Results 311 to 320 of about 3,512,914 (385)

Understanding Mechanisms of Whole Brain and Regional Grey Matter Atrophy in Children With MOGAD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the mechanisms driving whole brain and regional grey matter (GM) volume changes along with their clinical correlates in paediatric myelin oligodendrocyte glycoprotein antibody (MOG‐Ab)–associated disease (MOGAD). Methods One‐hundred‐nine paediatric MOGAD patients from two UK centres underwent MRI at attack nadir and ...
Ermelinda De Meo, Riccardo Nistri, Michael Eyre, Cheryl Hemingway, Ming Lim, Thomas Rossor, Asthik Biswas, Kshitij Mankad, Ata Siddiqui, Sniya Sudhakar, Declan Chard, Frederik Barkhof, Arman Eshaghi, Olga Ciccarelli, Yael Hacohen   +14 more
wiley   +1 more source

Rural and urban disparities in cardiovascular disease-related mortality in the USA over 20 years; have the trends been reversed by COVID-19?

International Journal of Cardiology. Cardiovascular Risk and Prevention, 2023
Saisunder S. Chaganty, Dmitry Abramov, Harriette G.C. Van Spall, Renee P. Bullock-Palmer, Vassilios Vassiliou, Phyo Kyaw Myint, Vijay Bang, Ofer Kobo, Mamas A. Mamas   +8 more
doaj  

A multi-omics prognostic model of cuproptosis affects the prognosis of stomach adenocarcinoma. [PDF]

Clin Epigenetics
Wu Y, Fan Y, Dong X, Dong D, Shi Y, Wang M, Wang J, Yang Y, Yang N, Ou F, Li E.   +10 more
europepmc   +1 more source

Prognosis in Conservatively Treated Sciatica

, 1956
Lennart Söderberg
openalex   +1 more source

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

CA199 and CEA expression levels, and minimally invasive postoperative prognosis analysis in esophageal squamous carcinoma patients. [PDF]

Open Med (Wars)
Ji C, Ji L, Wang F, Zhang A, Shen L.
europepmc   +1 more source

A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester, Kevin Talbot, Martin R. Turner, Alexander G. Thompson, the Pooled Resource Open‐Access ALS Clinical Trials Consortium   +4 more
wiley   +1 more source

Rare Head and Neck Neuroendocrine Neoplasms: A Retrospective Study of Prognosis and Treatment Outcomes. [PDF]

Cancer Diagn Progn
Matsuo M, Tsuchihashi K, Miyamoto Y, Hashimoto K, Kogo R, Komune N, Sato M, Masuda S, Nakagawa T.   +8 more
europepmc   +1 more source

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source

A comprehensive analysis of transcription factors identified TCF3 as a prognostic target for glioma. [PDF]

Sci Rep
Li Q, Feng P, Liu S, Tian G, Yuan G, Pan Y.   +5 more
europepmc   +1 more source